Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia 2 Breast Neoplasms 2 Vomiting 1 Uterine Cervical Neoplasms 1 Trigger Finger Disorder 1 Sarcoma, Alveolar Soft Part 1 Renal Insufficiency 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Pain 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nausea 1 Mucositis 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Mast-Cell 1 Leukemia, Hairy Cell 1

Interventions

Cyclophosphamide 241 Rituximab 223 Etoposide 138 Filgrastim 113 Vincristine 112 Doxorubicin 104 Prednisone 90 Cytarabine 90 Methotrexate 79 fludarabine phosphate 77 Radiotherapy 76 Peripheral Blood Stem Cell Transplantation 71 Melphalan 71 Busulfan 60 Tacrolimus 48 Dexamethasone 48 Mycophenolic Acid 46 Carmustine 46 Granulocyte Colony-Stimulating Factor 44 fludarabine 43 Antilymphocyte Serum 40 Ifosfamide 38 sargramostim 34 Whole-Body Irradiation 34 Cyclosporine 33 Bortezomib 32 Gemcitabine 30 Methylprednisolone 27 Bendamustine Hydrochloride 27 Lenalidomide 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × Acetaminophen × Clear all

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Stanford University

Phase 2 Completed

9 enrolled 10 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡